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Restoring essential ecosystem services is a key goal of environmental managers following a 
disaster such as a forest fire. The recent attention being paid to the indigenous human 
microbiota, the collection of microbes that live in and on the human body, has driven a 
desire to understand the role that this microbial community can play in human health and 
disease [1, 2]. Changes in this human/microbial ecosystem are associated with various 
diseases and thus there is a desire to restore a “beneficial” community in order to restore 
health.
One of the key ecosystem services provided by the indigenous microbiota is that of 
providing colonization resistance [3]. Defined as the ability of an established community of 
microbes to prevent the establishment of additional potentially pathogenic microbes, 
colonization resistance is thought to be an essential defense mechanism against a variety of 
infectious diseases. Perhaps the best example of the loss of colonization resistance is the 
development of C. difficile infection (CDI) in patients whose indigenous gut microbiota is 
disrupted via the administration of antibiotics [4]. While the majority of patients with CDI 
respond to antibiotic therapy directed against the pathogen, recurrent disease whereby 
patients experience a recrudescence of symptoms after discontinuing anti-C. difficile therapy 
can be a major problem. In patients who remain unresponsive to additional rounds of 
treatment, restoration of the intestinal microbiota through the administration of feces 
obtained from a normal donor is a successful and viable alternative treatment [5].
Although there has been considerable recent attention paid to the use of fecal microbiota 
transplantation (FMT) for C. difficile it should be noted that the use of fecal transplantation 
to treat antibiotic-associated pseudomembranous colitis predates the recognition that this 
clinical entity was often due to CDI. A case series of four patients who were successfully 
treated by healthy donor feces administered via enema was published in 1958 by Eiseman 
and colleagues [6]. A more recent development has been the attempted use of FMT to 
eliminate colonization or treat infections with multiply drug-resistant organisms (MDROs) 
such as vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus 
aureus (MRSA) and Enterobacteriaceae that harbor carbapenamases or extended-spectrum 
beta-lactamases (ESBLs). In this issue of Infectious Diseases [7], Manges and colleagues 
review eight recent case reports/case series where fecal transplantation was used to 
decolonize patients with an enteric MDRO. In the published reports that they review, the 
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authors note that there was considerable success although they acknowledge that there could 
be a bias against reporting negative results.
Given the fact that the review [7] focuses on the available published literature on the use of 
FMT for eliminating MDRO colonization and that this evidence consists solely of small case 
series and case reports, some of which were not peer-reviewed, it could be asked if it is far 
too early to review this area. However, the authors take the opportunity to identify and 
discuss several key questions regarding the practical use of FMT to eliminate MDRO 
colonization and also point to future needs and directions for research. We will spend some 
time here reviewing these future directions and presenting some of our own ideas regarding 
further developments in this area.
Manges and colleagues identify three practical considerations regarding FMT 
administration: 1) the route of administration, 2) donor selection and 3) the need for bowel 
preparation in the recipient. They rightfully point out that the experience using FMT for 
treatment of recurrent CDI may not necessarily apply to decolonizing patients with MRDOs 
due to potential differences in the mechanisms by which the indigenous microbiota mediates 
colonization resistance against various organisms. For recurrent CDI, variability in 
approaches to the three practical concerns raised above does not appear to have a significant 
effect on the efficacy of FMT. Even given potential publication bias in favor of positive 
results, the eight case reports reviewed by Manges et al have a remarkable success rate, on 
par with the early case reports and case series of the use of FMT for recurrent CDI, and 
suggesting that FMT for elimination of MDRO carriage may yield similarly robust results. 
We agree that larger clinical trials of FMT for MDRO decolonization are needed and it is 
important to note that the authors identified five trials that are currently enrolling patients for 
such studies. Hopefully these studies will provide better quality results on the efficacy of 
FMT for eradication of MDROs in a manner analogous to the first large, controlled trial for 
FMT in recurrent CDI [8]. An additional line of human study involves a more detailed 
examination of the specific changes in the gut microbiota that are associated with 
susceptibility to MDRO colonization, and of exposures such as antibiotic treatment that may 
be risk factors for these changes. McDonald and colleagues recently published a report that 
suggested that the establishment of a “microbiome disruption index” might be able to 
improve prevention of infection with MDROs by identifying patients at greatest risk for 
colonization based on the status of the community structure of the gut microbiota [9]. Such 
patients could be targeted for interventions such as antibiotic stewardship, probiotic 
administration, or even FMT with the goal of restoring a colonization-resistant microbial 
community. Only additional studies can determine whether this will turn out to be a viable 
strategy.
Long-term observational studies are also needed to evaluate whether FMT eradicates MDRO 
carriage or merely suppresses it below the limit of detection, with recrudescence possible 
after subsequent re-exposure to antibiotics or other stressors. As discussed by Manges and 
colleagues [7], even temporary suppression of MDRO colonization would have the potential 
benefit of protecting patients from invasive infection during vulnerable clinical periods, such 
as prolonged neutropenia after myeloablative cancer chemotherapy, and of reducing the risk 
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that a colonized patient would act as a source of MDRO cross-transmission during hospital 
stays requiring substantial hands-on care, such as during critical illness.
In addition to human clinical trials and natural history studies, we think that more 
mechanistic studies of the role of the microbiota in establishing colonization resistance 
against MDROs are also needed. Using the case of CDI once again, the use of small animal 
models (generally hamster and mouse models of CDI) has provided important information 
of the mechanisms by which the indigenous gut microbiota can prevent colonization by C. 
difficile [10]. Manges et al. suggest that in the future “a clearly defined and regulated 
complex mixture of functional microbiota organisms” could be developed for elimination of 
MDRO colonization. In order to better define the important functions that are needed to 
eliminate MDROs, animal models are likely to have great utility. Returning to CDI, the role 
of bile acids in mediating colonization resistance against C. difficile has been defined in 
rodent models of disease [11]. Also the role of the microbiota modulating protective 
intestinal immune responses has been shown in a murine model [12]. A recent publication 
has demonstrated that administration of vancomycin to alter the gut microbiota can render 
mice susceptible to colonization with VRE and carbapenam-resistant Klebsiella [13]. Thus 
there is every reason to think that a greater understanding of the molecular mechanisms 
desirable to be possessed by a “designer microbiome-based therapy” could come from the 
use of animal models.
A final point raised by Manges et al. is that the legal, regulatory and safety issues associated 
with FMT (and any microbiota-targeting therapy for that matter) are underappreciated. We 
agree that this is an important consideration. In particular, the regulatory aspects of FMT 
have the potential to block widespread implementation of this promising therapeutic 
alternative for the treatment and prevention of important nosocomial infections [14]. 
Additionally this would have repercussions for the use of microbiome-targeting therapy for a 
variety of non-infectious conditions. It should be recognized that ethical concerns related to 
FMT for treatment of asymptomatic MDRO decolonization may be different from those 
related to treatment of severe, recurrent CDI. Only about 20% of intensive care unit (ICU) 
patients who are colonized with an MDRO develop an infection with the same MDRO 
during their ICU stay [15, 16]; the risk of infection may be lower among patients in long 
term care facilities [17, 18], which have been identified as important reservoirs for MDROs 
in several studies [19]. While FMT holds promise as a groundbreaking strategy for control 
of MDROs in these settings, its therapeutic index must be proven to be very high before 
treatment of asymptomatic patients who may be at low risk of infection can be justified.
We would like to join with Manges and colleagues in calling for active discussion between 
investigators, clinicians and regulatory bodies including the US Food and Drug 
Administration to be proactive in considering the ethical, legal and social issues surrounding 
the use of FMT and other therapies that may alter the microbiota. These are exciting times 
for reconsidering mechanisms of disease pathogenesis and developing novel preventative 
and therapeutic approaches that are based on an understanding of the intricacies of the 
interaction between humans and their indigenous microbial partners.
Young and Hayden Page 3
Infect Dis (Lond). Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
 Acknowledgments
This work was supported in part by U54 CK000161 04S2 to MKH and U19 AI090871 to VBY
References
1. Eloe-Fadrosh EA, Rasko DA. The human microbiome: from symbiosis to pathogenesis. Annu Rev 
Med. 2013; 64:145–63. [PubMed: 23327521] 
2. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 
2012; 13:260–70. [PubMed: 22411464] 
3. Lawley TD, Walker AW. Intestinal colonization resistance. Immunology. 2013; 138:1–11. [PubMed: 
23240815] 
4. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by 
Clostridium difficile. Gastroenterology. 2014; 146:1547–53. [PubMed: 24503131] 
5. Rao K, Young VB. Fecal Microbiota Transplantation for the Management of Clostridium difficile 
Infection. Infect Dis Clin North Am. 2015; 29:109–22. [PubMed: 25677705] 
6. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of 
pseudomembranous enterocolitis. Surgery. 1958; 44:854–9. [PubMed: 13592638] 
7. Manges AR, Steiner TS, Wright AJ. Fecal microbiota transplantation for the intestinal 
decolonization of extensively antimicrobial resistant opportunistic pathogens: a review. Infect Dis 
(London). 2016; 48:xxx–xxx.
8. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal 
infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013; 368:407–15. 
[PubMed: 23323867] 
9. Halpin AL, de Man TJ, Kraft CS, Perry KA, Chan AW, Lieu S, et al. Intestinal microbiome 
disruption in patients in a long-term acute care hospital: A case for development of microbiome 
disruption indices to improve infection prevention. Am J Infect Control. Feb 19.2016 [Epub ahead 
of print]. 
10. Lawley TD, Young VB. Murine models to study Clostridium difficile infection and transmission. 
Anaerobe. 2013; 24:94–7. [PubMed: 24076318] 
11. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, et al. Precision microbiome 
reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015; 
517:205–8. [PubMed: 25337874] 
12. Abt MC, Lewis BB, Caballero S, Xiong H, Carter RA, Susac B, et al. Innate Immune Defenses 
Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile 
Infection. Cell Host Microbe. 2015; 18:27–37. [PubMed: 26159718] 
13. Lewis BB, Buffie CG, Carter RA, Leiner I, Toussaint NC, Miller LC, et al. Loss of Microbiota-
Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin 
Compared With Metronidazole. J Infect Dis. 2015; 212:1656–65. [PubMed: 25920320] 
14. Vyas D, Aekka A, Vyas A. Fecal transplant policy and legislation. World J Gastroenterol. 2015; 
21:6–11. [PubMed: 25574076] 
15. Thom KA, Johnson JA, Strauss SM, Furuno JP, Perencevich EN, Harris AD. Increasing prevalence 
of gastrointestinal colonization with ceftazidime-resistant gram-negative bacteria among intensive 
care unit patients. Infect Control Hosp Epidemiol. 2007; 28:1240–6. [PubMed: 17926274] 
16. Safdar N, Bradley EA. The risk of infection after nasal colonization with Staphylococcus aureus. 
Am J Med. 2008; 121:310–5. [PubMed: 18374690] 
17. Manning S, Lautenbach E, Tolomeo P, Han JH. Risk factors for infection with Escherichia coli in 
nursing home residents colonized with fluoroquinolone-resistant E. coli. Infect Control Hosp 
Epidemiol. 2015; 36:575–7. [PubMed: 25880678] 
18. Elizaga ML, Weinstein RA, Hayden MK. Patients in long-term care facilities: a reservoir for 
vancomycin-resistant enterococci. Clin Infect Dis. 2002; 34:441–6. [PubMed: 11797169] 
19. Kahvecioglu D, Ramiah K, McMaughan D, Garfinkel S, McSorley VE, Nguyen QN, et al. 
Multidrug-resistant organism infections in US nursing homes: a national study of prevalence, 
Young and Hayden Page 4
Infect Dis (Lond). Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
onset, and transmission across care settings, October 1, 2010-December 31, 2011. Infect Control 
Hosp Epidemiol. 2014; 35(Suppl 3):S48–55. [PubMed: 25222898] 
Young and Hayden Page 5
Infect Dis (Lond). Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
